AU2019343044B2 - Combination therapy for treating blood cancer - Google Patents

Combination therapy for treating blood cancer Download PDF

Info

Publication number
AU2019343044B2
AU2019343044B2 AU2019343044A AU2019343044A AU2019343044B2 AU 2019343044 B2 AU2019343044 B2 AU 2019343044B2 AU 2019343044 A AU2019343044 A AU 2019343044A AU 2019343044 A AU2019343044 A AU 2019343044A AU 2019343044 B2 AU2019343044 B2 AU 2019343044B2
Authority
AU
Australia
Prior art keywords
bcl
inhibitor
formula
family protein
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019343044A
Other languages
English (en)
Other versions
AU2019343044A1 (en
Inventor
Xiaoyan Jiang
Xiaojia NIU
Katharina ROTHE
Zaihui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signalchem Lifesciences Corp
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of AU2019343044A1 publication Critical patent/AU2019343044A1/en
Application granted granted Critical
Publication of AU2019343044B2 publication Critical patent/AU2019343044B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019343044A 2018-09-18 2019-09-18 Combination therapy for treating blood cancer Active AU2019343044B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732816P 2018-09-18 2018-09-18
US62/732,816 2018-09-18
PCT/US2019/051764 WO2020061216A1 (en) 2018-09-18 2019-09-18 Combination therapy for treating blood cancer

Publications (2)

Publication Number Publication Date
AU2019343044A1 AU2019343044A1 (en) 2021-03-18
AU2019343044B2 true AU2019343044B2 (en) 2025-03-06

Family

ID=68104787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019343044A Active AU2019343044B2 (en) 2018-09-18 2019-09-18 Combination therapy for treating blood cancer

Country Status (13)

Country Link
US (1) US12097194B2 (enExample)
EP (1) EP3852766B1 (enExample)
JP (1) JP7460639B2 (enExample)
KR (1) KR102764125B1 (enExample)
CN (1) CN112739349B (enExample)
AU (1) AU2019343044B2 (enExample)
BR (1) BR112021005054A2 (enExample)
CA (1) CA3110901C (enExample)
IL (1) IL281439B2 (enExample)
MX (1) MX2021003062A (enExample)
SG (1) SG11202101955SA (enExample)
TW (1) TWI824010B (enExample)
WO (1) WO2020061216A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
EP4054585A1 (en) 2019-11-05 2022-09-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof
TW202545523A (zh) * 2024-02-05 2025-12-01 加拿大商聖諾康生命科學公司 用於治療血液癌症之組合療法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170022189A1 (en) * 2013-11-27 2017-01-26 Signalchem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
BRPI1007046B1 (pt) 2009-01-16 2019-07-16 Rigel Pharmaceuticals, Inc. Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9993472B2 (en) * 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170022189A1 (en) * 2013-11-27 2017-01-26 Signalchem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHARMA P. et al. "Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition", CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018) vol. 13, no. 4, pages 256-264 *

Also Published As

Publication number Publication date
US20220031685A1 (en) 2022-02-03
WO2020061216A1 (en) 2020-03-26
CA3110901C (en) 2024-01-02
IL281439A (en) 2021-04-29
KR102764125B1 (ko) 2025-02-07
IL281439B1 (en) 2024-10-01
IL281439B2 (en) 2025-02-01
JP7460639B2 (ja) 2024-04-02
US12097194B2 (en) 2024-09-24
SG11202101955SA (en) 2021-03-30
EP3852766B1 (en) 2024-05-08
JP2022501434A (ja) 2022-01-06
EP3852766A1 (en) 2021-07-28
CA3110901A1 (en) 2020-03-26
TW202023554A (zh) 2020-07-01
TWI824010B (zh) 2023-12-01
BR112021005054A2 (pt) 2021-06-08
MX2021003062A (es) 2021-05-27
AU2019343044A1 (en) 2021-03-18
CN112739349A (zh) 2021-04-30
KR20210061356A (ko) 2021-05-27
CN112739349B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
US12097194B2 (en) Combination therapy for treating blood cancer
AU2019315487B2 (en) Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xl dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases
US20230346790A1 (en) Pharmaceutical composition for prevention or treatment of cancers associated with kras mutation
ES2806135T3 (es) Nuevos inhibidores de bromodominios bicíclicos
US9328106B2 (en) Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
KR20240055778A (ko) Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
RU2638552C2 (ru) Пиразол-4-ил-гетероциклил-карбоксамидные соединения и способы применения
JP7241747B2 (ja) 血液学的障害を治療するための化合物および組成物
CN115996716A (zh) Eif4a抑制剂组合
ES3048084T3 (en) Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
JP2020512343A (ja) 血液疾患を処置するための化合物及び組成物
BR112019019101A2 (pt) compostos macrocíclicos como inibidores de ros1 cinase
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
AU2012357339B2 (en) Tri-heterocyclic derivatives, preparation process and uses thereof
WO2017007658A1 (en) A combination for immune mediated cancer treatment
BR112021002632A2 (pt) compostos e composições de ureia como inibidores de smarca2/brm atpase
TW202031253A (zh) 治療黑色素瘤的藥物組合
BR112014021519B1 (pt) Compostos de piperidina ou sais dos mesmos e inibidor seletivo de aurora a, composição farmacêutica, agente antitumoral e agente de potencialização de efeito antitumoral de um agonista de microtúbulos compreendendo os ditos compostos, bem como usos terapêuticos dos ditos composto
AU2016287587B2 (en) Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use
CN112237579A (zh) 药物组合及其用途
HK40042345A (en) Combination therapy for treating blood cancer
HK40042345B (en) Combination therapy for treating blood cancer
KR20200084899A (ko) 단백질 키나제에 대한 억제 활성을 갖는 티에노[3,2-d]피리미딘 화합물
US20160143895A1 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
HK40035225A (en) Pharmaceutical combination and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)